Avida Global (AG) is a Business-to-Business (B2B) producer of high-quality medicinal cannabis oils and derivatives for the global medical, well-being and cosmeceutical markets. The company has a cultivation and processing facility in North-East Colombia. It asserts that the therapeutic properties of the cannabis plant has driven 53 countries to legalise its use, with more to follow. AG seeks to capture this demand and become a contender in the medicinal cannabis market that is expected to soar from $33.1 billion to $84.0 billion by 2028. The company has received regulatory approvals for initial non-psychoactive cannabis cultivation, manufacturing, and export licences in 2019. It is working on a partnership with a medicinal cannabis prescriber through doctors and clinics for the supply of medicinal cannabis strains in the UK. The company will use 40% of the investment to drive revenue growth, 25% as capital expenses, and 35% as additional operating expenses.
days to go:
Expired
investment:
£1,646,249
HaMuch is an online platform that lets homeowners compare hourly rates of local tradespeople and check their availability. The company has provided digital marketing services to businesses such as Travis Perkins, HomeServe, and Rated People. About 200,000 tradespeople have uploaded their profiles on the platform with 12,000+ having uploaded their respective prices. The company has been featured in The Sunday Telegraph, Express, Sun, and Microsoft News.
days to go:
Expired
investment:
£132,850
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Lifetise is a financial planning platform that enables prospective clients to plan significant expenditures such as buying a home, marital expenses, child-rearing and retirement. Presently, they have come up with two major offerings: Homefinder and Childminder. The first one acts as a tool that shows money required to afford a home in the UK and the amount of time taken to save the money while the latter helps parents to calculate the costs of childcare along with their work. Lifetise is targeting the 25-40 age group in the UK whose population numbers are approximately 14 million. To date, they have been featured in prominent publications like Evening Standard and Stylist with an active following on Reddit. The company has secured 12,000 customers after their partnering with Accenture's Fintech Accelerator Programme. With the investment, Lifetise will spend more on developing its applications with a focus on all major life expenditures, marketing on social media channels, build partnerships and human resources.
days to go:
Expired
investment:
£254,240
YoungPlanet enables parents to put their children's unused things to use with new families and away from landfills for free via its app. The company cites PwC data estimating the UK’s sharing economy to be worth £9 billion by 2025. It aims to be a contender in this segment. The company argues further that 10-year-olds in the UK will own on average 238 toys at any one time and yet play with just 12. This leads to UK households wasting over 25 million tonnes a year, with one-fourth of this number ending up in landfills as per the Department for Environment, Food and Rural Affairs (DEFRA). YoungPlanet aims to change this. It has onboarded 36,000 users on its platform to date and featured in press publications such as BBC News, Vanessa Feltz, and LadBible. YoungPlanet will use the investment to scale nationally, begin generating first phase revenue via brand sponsorship of events, branded gamification, and Business-to-Business (B2B) subscriptions for semi-closed communities via its app.
days to go:
Expired
investment:
£547,103
Equipsme is a company that aims to democratise health insurance by making it affordable for businesses. The company offers flexible fixed-price packages to employees while giving them the option to upgrade their package to avail more features upon payment. Members can speak to a general physician round the clock, have physiotherapy sessions, avail regular health checks and, if necessary, be quickly referred to a consultant for diagnosis and treatment. Members can access these features through a simple-to-use application. Since February 2018, the company has secured an exclusive 5-year insurance capacity deal with AXA PPP Healthcare and grown its members by 130.5% Year-on-Year (YoY) (to May 2020) with a 95% broker renewal retention rate. The company will use the investment to enhance its user experience and scale its marketing as it announces its partnerships with organisations such as Starling Bank and Simply Business.
days to go:
Expired
investment:
£879,204
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
AndCo offers an open-source, cost-effective, sustainable solution to co-working by turning hotel lobbies and lavish eateries into co-working spaces all over London. The company has over 90 venues, over 1200 members and over 10 brand partnerships. It has been featured major publications including The Telegraph, Forbes, and The Metro. The funds raised will be used for marketing, development, hiring new teammates and working capital.
days to go:
Expired
investment:
£269,231
Equipsme is on a mission to democratise health insurance by making it affordable for businesses of all sizes. The company cites data arguing that there has been a 53% increase in National Health Service (NHS) treatment waiting lists since 2012 due to the low reach of health insurance by conventional insurance companies. It aims to change this scenario. Equipsme offers flexible fixed-price packages to companies wherein employees are allowed to upgrade and add family members to their plan as per their pleasure. Members can also speak to a General Physician (GP) 24/7, and, if necessary, be referred to a consultant for diagnosis and treatment through the company's proprietary app. The company was felicitated with the 'Best New Product' award by Cover Magazine Excellence Awards 2019. The company will use the investment to enhance its user experience, ensure its technology remains market-leading, and scale its marketing and customer service capability.
days to go:
Expired
investment:
£286,096
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
